[{"id":"5d9596a1-d384-4d3e-99e8-4001de1a4302","acronym":"EVOLVE CLL/SLL","url":"https://clinicaltrials.gov/study/NCT04269902","created_at":"2021-01-18T20:44:42.322Z","updated_at":"2025-02-25T12:27:29.630Z","phase":"Phase 3","brief_title":"Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study","source_id_and_acronym":"NCT04269902 - EVOLVE CLL/SLL","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation • IGH mutation","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 247","initiation":"Initiation: 03/02/2021","start_date":" 03/02/2021","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2025-02-24"},{"id":"30691860-7f81-43a1-b334-a75b53b70fce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04959175","created_at":"2021-07-13T12:53:21.217Z","updated_at":"2025-02-25T13:40:32.157Z","phase":"Phase 1/2","brief_title":"Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies","source_id_and_acronym":"NCT04959175","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • IGH","pipe":"","alterations":" ","tags":["EGFR • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • mesna • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 09/23/2021","start_date":" 09/23/2021","primary_txt":" Primary completion: 04/27/2027","primary_completion_date":" 04/27/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-21"},{"id":"afc34dd5-440d-4768-b2d3-1f68bbdafbb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05470491","created_at":"2022-07-22T11:56:13.684Z","updated_at":"2025-02-25T13:54:33.177Z","phase":"Phase 1/2","brief_title":"Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...","source_id_and_acronym":"NCT05470491","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IGH","pipe":"","alterations":" ","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • Selzentry (maraviroc) • plerixafor"],"overall_status":"Recruiting","enrollment":" Enrollment 265","initiation":"Initiation: 01/26/2023","start_date":" 01/26/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2027","study_completion_date":" 07/30/2027","last_update_posted":"2025-02-20"},{"id":"be1f4791-7f5f-42b3-86ee-a6bfee99acee","acronym":"ASSURE","url":"https://clinicaltrials.gov/study/NCT04008706","created_at":"2021-01-18T19:41:49.844Z","updated_at":"2025-02-25T14:07:28.508Z","phase":"Phase 3","brief_title":"Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients","source_id_and_acronym":"NCT04008706 - ASSURE","lead_sponsor":"AstraZeneca","biomarkers":" TP53 • CD20 • IGH • CD5 • FCER2","pipe":" | ","alterations":" Chr del(17p) • Chr del(11q) • IGH mutation","tags":["TP53 • CD20 • IGH • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr del(11q) • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 552","initiation":"Initiation: 09/17/2019","start_date":" 09/17/2019","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-17"},{"id":"c7c82407-4fb1-4d5b-8ceb-ae8beb683ec2","acronym":"CLL registry","url":"https://clinicaltrials.gov/study/NCT05140369","created_at":"2021-12-01T14:53:37.838Z","updated_at":"2025-02-25T15:12:29.051Z","phase":"","brief_title":"CLL Therapy Approaches in Russia","source_id_and_acronym":"NCT05140369 - CLL registry","lead_sponsor":"AstraZeneca","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 6000","initiation":"Initiation: 10/29/2021","start_date":" 10/29/2021","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-13"},{"id":"23df8c55-37d1-4d81-9a8c-51e5c6811bf0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03983850","created_at":"2021-01-18T19:35:37.156Z","updated_at":"2025-02-25T15:26:05.857Z","phase":"Phase 1/2","brief_title":"Optimizing PTCy Dose and Timing","source_id_and_acronym":"NCT03983850","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • PTEN • IGH • FBXW7","pipe":" | ","alterations":" KRAS mutation • RAS mutation","tags":["KRAS • PTEN • IGH • FBXW7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • busulfan • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 07/09/2019","start_date":" 07/09/2019","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/29/2026","study_completion_date":" 05/29/2026","last_update_posted":"2025-02-11"},{"id":"814f07a4-6ae3-424e-b8de-ef7b7143e4c7","acronym":"BELLWAVE-010","url":"https://clinicaltrials.gov/study/NCT05947851","created_at":"2023-07-17T14:08:45.600Z","updated_at":"2025-02-25T15:28:11.395Z","phase":"Phase 3","brief_title":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","source_id_and_acronym":"NCT05947851 - BELLWAVE-010","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TP53 • BTK • IGH","pipe":" | ","alterations":" TP53 mutation • IGH mutation","tags":["TP53 • BTK • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • nemtabrutinib (MK-1026)"],"overall_status":"Recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 08/08/2023","start_date":" 08/08/2023","primary_txt":" Primary completion: 06/27/2033","primary_completion_date":" 06/27/2033","study_txt":" Completion: 06/27/2033","study_completion_date":" 06/27/2033","last_update_posted":"2025-02-11"},{"id":"6d960e71-ed2a-4ebb-b9a5-92e7b593b1dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02629809","created_at":"2021-01-18T12:47:12.967Z","updated_at":"2025-02-25T15:25:24.207Z","phase":"Phase 2","brief_title":"Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT02629809","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IGH","pipe":"","alterations":" ","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 03/18/2016","start_date":" 03/18/2016","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-10"},{"id":"cf9e772d-2d61-448f-ba42-778f71f83dc6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04169737","created_at":"2021-01-18T20:20:34.948Z","updated_at":"2025-02-25T15:26:14.343Z","phase":"Phase 2","brief_title":"Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT04169737","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation • Chr del(11q)","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 07/09/2026","primary_completion_date":" 07/09/2026","study_txt":" Completion: 07/09/2026","study_completion_date":" 07/09/2026","last_update_posted":"2025-02-10"},{"id":"9bf88391-bf8e-4bd2-b27f-b745a3c4ca24","acronym":"ECOG-ACRIN E1910","url":"https://clinicaltrials.gov/study/NCT02003222","created_at":"2021-01-18T09:08:51.217Z","updated_at":"2025-02-25T16:36:18.435Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02003222 - ECOG-ACRIN E1910","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CDKN2A • RUNX1 • IGH • ETV6 • CD4 • TCF3 • PBX1","pipe":"","alterations":" ","tags":["ABL1 • BCR • CDKN2A • RUNX1 • IGH • ETV6 • CD4 • TCF3 • PBX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 488","initiation":"Initiation: 05/19/2014","start_date":" 05/19/2014","primary_txt":" Primary completion: 06/23/2023","primary_completion_date":" 06/23/2023","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2025-02-06"},{"id":"a3defc3d-df49-43a3-8fb7-35111287e449","acronym":"NCI-2016-00797","url":"https://clinicaltrials.gov/study/NCT02756897","created_at":"2021-01-18T13:30:56.475Z","updated_at":"2025-02-25T17:23:07.242Z","phase":"Phase 2","brief_title":"Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia","source_id_and_acronym":"NCT02756897 - NCI-2016-00797","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation • Chr del(11q)","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 234","initiation":"Initiation: 07/07/2016","start_date":" 07/07/2016","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-01-31"},{"id":"da7c1c4e-12fb-4361-97e1-5845011e3482","acronym":"","url":"https://clinicaltrials.gov/study/NCT01243190","created_at":"2021-01-18T05:00:24.541Z","updated_at":"2025-02-25T13:16:23.958Z","phase":"Phase 2","brief_title":"Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","source_id_and_acronym":"NCT01243190","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IGH • CD38","pipe":" | ","alterations":" CD38 positive","tags":["IGH • CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 03/28/2023","primary_completion_date":" 03/28/2023","study_txt":" Completion: 03/28/2023","study_completion_date":" 03/28/2023","last_update_posted":"2024-09-19"},{"id":"63e0d60a-e16f-4451-bd50-7c30a33e2a8d","acronym":"BELLWAVE-008","url":"https://clinicaltrials.gov/study/NCT05624554","created_at":"2022-11-22T15:58:55.794Z","updated_at":"2024-07-02T16:34:25.934Z","phase":"Phase 3","brief_title":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)","source_id_and_acronym":"NCT05624554 - BELLWAVE-008","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" IGH mutation","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • Truxima (rituximab-abbs) • fludarabine IV • nemtabrutinib (MK-1026)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/16/2023","start_date":" 03/16/2023","primary_txt":" Primary completion: 05/19/2027","primary_completion_date":" 05/19/2027","study_txt":" Completion: 03/17/2031","study_completion_date":" 03/17/2031","last_update_posted":"2024-06-14"},{"id":"1a4083a5-4479-438a-a119-f10ee1b03fe4","acronym":"PICAROS","url":"https://clinicaltrials.gov/study/NCT05999877","created_at":"2023-08-21T15:08:51.118Z","updated_at":"2024-07-02T16:34:26.928Z","phase":"","brief_title":"PICAROS - Acalabrutinib RWE on 1L CLL in Spain","source_id_and_acronym":"NCT05999877 - PICAROS","lead_sponsor":"AstraZeneca","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation + Chr del(17p)","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation + Chr del(17p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 192","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-12"},{"id":"65f11ba4-54ff-43fd-a6f2-54316429b85b","acronym":"ECOG-ACRIN E1912","url":"https://clinicaltrials.gov/study/NCT02048813","created_at":"2021-01-17T17:35:11.745Z","updated_at":"2024-07-02T16:34:37.153Z","phase":"Phase 3","brief_title":"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT02048813 - ECOG-ACRIN E1912","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CCND1 • IGH • CD4 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14) • CD4 positive","tags":["CD20 • CCND1 • IGH • CD4 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CD4 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • cyclophosphamide • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 529","initiation":"Initiation: 02/20/2014","start_date":" 02/20/2014","primary_txt":" Primary completion: 10/24/2018","primary_completion_date":" 10/24/2018","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-07"},{"id":"03271227-2174-4789-a946-4de77e418a64","acronym":"","url":"https://clinicaltrials.gov/study/NCT04850846","created_at":"2021-04-20T14:55:37.601Z","updated_at":"2024-07-02T16:34:37.692Z","phase":"Phase 2","brief_title":"Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma","source_id_and_acronym":"NCT04850846","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IGH","pipe":"","alterations":" ","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/27/2021","start_date":" 04/27/2021","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-06-06"},{"id":"92222cde-38f1-4798-9e7b-0b2b4361f314","acronym":"","url":"https://clinicaltrials.gov/study/NCT05436418","created_at":"2022-06-29T15:59:10.686Z","updated_at":"2024-07-02T16:34:38.201Z","phase":"Phase 1/2","brief_title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","source_id_and_acronym":"NCT05436418","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IGH • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["IGH • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 11/18/2022","start_date":" 11/18/2022","primary_txt":" Primary completion: 06/25/2027","primary_completion_date":" 06/25/2027","study_txt":" Completion: 07/02/2027","study_completion_date":" 07/02/2027","last_update_posted":"2024-06-05"},{"id":"14b28ae8-831d-4306-9aa4-5c102afbfa3f","acronym":"CARPALL","url":"https://clinicaltrials.gov/study/NCT02443831","created_at":"2021-01-18T11:42:34.871Z","updated_at":"2024-07-02T16:35:00.037Z","phase":"Phase 1","brief_title":"CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies","source_id_and_acronym":"NCT02443831 - CARPALL","lead_sponsor":"University College, London","biomarkers":" ABL1 • BCR • KMT2A • IGH • CD22 • TCF3","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement","tags":["ABL1 • BCR • KMT2A • IGH • CD22 • TCF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AUTO1/22 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2036","study_completion_date":" 12/31/2036","last_update_posted":"2024-05-30"},{"id":"cbf25b80-812c-4077-9111-bd170e1a9071","acronym":"","url":"https://clinicaltrials.gov/study/NCT03219450","created_at":"2021-01-18T15:53:18.906Z","updated_at":"2025-02-25T16:06:35.068Z","phase":"Phase 1","brief_title":"A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.","source_id_and_acronym":"NCT03219450","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IGH","pipe":" | ","alterations":" IGH mutation","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • Neo Vax (NEO-PV-01) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 08/18/2021","start_date":" 08/18/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2024-04-23"},{"id":"5bfa33a7-a18f-4107-bd58-43f163eb2f7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04136275","created_at":"2021-01-18T20:18:20.206Z","updated_at":"2024-07-02T16:35:15.066Z","phase":"Phase 1","brief_title":"CAR-37 T Cells In Hematologic Malignancies","source_id_and_acronym":"NCT04136275","lead_sponsor":"Marcela V. Maus, M.D.,Ph.D.","biomarkers":" TP53 • IGH • CD5 • CD37","pipe":" | ","alterations":" TP53 mutation • CD37 expression","tags":["TP53 • IGH • CD5 • CD37"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD37 expression"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 06/19/2020","start_date":" 06/19/2020","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2024-03-13"},{"id":"6d4a3258-2b1b-4296-b36c-80ae974d4943","acronym":"","url":"https://clinicaltrials.gov/study/NCT04501614","created_at":"2021-01-18T21:33:45.485Z","updated_at":"2024-07-02T16:35:16.674Z","phase":"Phase 1/2","brief_title":"A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04501614","lead_sponsor":"Takeda","biomarkers":" ABL1 • BCR • IGH • PDGFRB • CSF1R • PIAS4","pipe":" | ","alterations":" BCR-ABL1 fusion • BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation","tags":["ABL1 • BCR • IGH • PDGFRB • CSF1R • PIAS4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion • BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Iclusig (ponatinib) • cyclophosphamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 02/24/2021","start_date":" 02/24/2021","primary_txt":" Primary completion: 12/19/2024","primary_completion_date":" 12/19/2024","study_txt":" Completion: 01/04/2027","study_completion_date":" 01/04/2027","last_update_posted":"2024-03-04"},{"id":"d5be950f-3675-484f-9cf0-33481c11c95d","acronym":"NCI-2011-03562","url":"https://clinicaltrials.gov/study/NCT01527149","created_at":"2021-01-18T06:26:25.305Z","updated_at":"2024-07-02T16:35:20.370Z","phase":"Phase 2","brief_title":"Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT01527149 - NCI-2011-03562","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD20 • CCND1 • IGH • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14) • CD20 expression","tags":["CD20 • CCND1 • IGH • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • dexamethasone • Arzerra (ofatumumab) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 12/06/2011","start_date":" 12/06/2011","primary_txt":" Primary completion: 04/26/2018","primary_completion_date":" 04/26/2018","study_txt":" Completion: 01/11/2024","study_completion_date":" 01/11/2024","last_update_posted":"2024-02-07"},{"id":"bf103e0b-eb69-4601-9153-c25f524eb238","acronym":"","url":"https://clinicaltrials.gov/study/NCT05388006","created_at":"2022-05-24T12:54:30.533Z","updated_at":"2024-07-02T16:35:24.113Z","phase":"Phase 2","brief_title":"Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT05388006","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • CCND1 • IGH • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD20 • CCND1 • IGH • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imfinzi (durvalumab) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 06/15/2022","start_date":" 06/15/2022","primary_txt":" Primary completion: 11/15/2024","primary_completion_date":" 11/15/2024","study_txt":" Completion: 11/15/2025","study_completion_date":" 11/15/2025","last_update_posted":"2024-01-09"},{"id":"e11fa619-feab-4b71-950e-0952bd0a0f35","acronym":"","url":"https://clinicaltrials.gov/study/NCT02332980","created_at":"2021-01-18T11:04:34.890Z","updated_at":"2024-07-02T16:35:24.706Z","phase":"Phase 2","brief_title":"Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas","source_id_and_acronym":"NCT02332980","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • PD-1 • CCND1 • IGH • PD-L2 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD20 • PD-1 • CCND1 • IGH • PD-L2 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imbruvica (ibrutinib) • Zydelig (idelalisib)"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 02/19/2015","start_date":" 02/19/2015","primary_txt":" Primary completion: 08/10/2021","primary_completion_date":" 08/10/2021","study_txt":" Completion: 01/04/2022","study_completion_date":" 01/04/2022","last_update_posted":"2024-01-03"}]